Biogenity ApS: Financial statements 2019
CVR: 39606925
Source: annual report 2019, Danish Business Authority
30/05/2018 – 30/06/2019
Biogenity ApS (CVR 39606925) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -71,498 and a net result of DKK 141,285. Equity in the 2019 report amounted to DKK 141,288. The solvency ratio was 76.6%.
- Gross Profit
- DKK -71,498
- Profit/Loss
- DKK 141,285
- Equity
- DKK 141,288
- Total Assets
- DKK 184,337
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of June 25, 2019, Søren Buch Jensen has left the board of directors of Biogenity ApS.
As of June 25, 2019, Søren Buch Jensen has stepped down as director of Biogenity ApS.
As of April 1, 2019, Søren Buch Jensen has joined the board of directors of Biogenity ApS.
As of April 1, 2019, Søren Buch Jensen is registered as director of Biogenity ApS.
About Biogenity ApS
Biogenity ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kenneth Kastaniegaard and Louis Loeb. The board consists of Louis Loeb (chair) and Kenneth Kastaniegaard. The company is owned by L.Loeb Holding ApS and Kastaniegaard Holding ApS. According to the 2025 annual report, the company had an average of 4 employees. In 2025, the company reported a gross profit of DKK 1,387,873 and a net result of DKK -453,753 compared with DKK -342,877 the year before. Equity in the 2025 report amounted to DKK -189,867.